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Background: The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are associated with improved
outcome in patients with peripheral arterial disease. Statins may also have beneficial properties beyond their lipid-
lowering effect.
Methods: A prospective, observational cohort study was conducted at a university hospital from 1990 to 2005 to examine
whether higher doses of statins and lower low-density lipoprotein (LDL) cholesterol levels are both independently
associated with improved outcome in peripheral arterial disease. Enrolled were 1374 consecutive patients (age, 61  10
years, 73%male) with peripheral arterial disease (ankle-brachial index<0.90). They were screened for clinical risk factors,
statin therapy, and LDL cholesterol levels. Serial LDL cholesterol levels were measured at 6 months and yearly after
enrollment. The mean follow-up time was 6.4 3.6 years, and no patients were lost to follow-up. The primary end points
were all-cause and cardiac mortality. The secondary end point was the progression to kidney failure.
Results: Overall mortality, cardiac death, and progression to kidney failure occurred in 29%, 20%, and 5% of patients,
respectively. Multivariate analysis revealed that higher doses of statins (per 10% increase) and lower 6-month LDL
cholesterol levels (per 10 mg/dL decrease) were both independently associated with lower all-cause mortality (hazard
ratio [HR], 0.71; 95% confidence interval [CI], 0.62 to 0.80; and HR, 0.96; 95% CI, 0.93 to 0.98, respectively) and
cardiac death (HR, 0.76; 95% CI, 0.67 to 0.86; and HR, 0.95; 95% CI, 0.92 to 0.98, respectively). Higher high-density
lipoprotein cholesterol levels also correlated significantly with lower all-cause and cardiac mortality. Higher doses of
statins (per 10% increase) were associated with less progression to kidney failure (HR, 0.69; 95% CI, 0.54 to 0.89).
Conclusions: Higher doses of statins and lower LDL cholesterol levels are both independently associated with improved
outcome in patients with peripheral arterial disease. These results support the view that statins have beneficial effects
beyond their lipid-lowering properties and should be considered in all patients with PAD, irrespective of LDL cholesterol
levels. ( J Vasc Surg 2007;45:936-43.)The beneficial properties of 3-hydroxy-3-methylglu-
taryl coenzyme A reductase inhibitors (statins) beyond
their lipid-lowering effect include atherosclerotic plaque
stabilization, oxidative stress reduction, and a decrease in
vascular inflammation.1 Studies have shown that a reduc-
tion in the inflammatory component through the use of
statins improves the clinical outcome in patients with cor-
onary artery disease.2,3
Peripheral arterial disease (PAD) is a manifestation of
systemic atherosclerosis and has been recognized as a
growing health burden worldwide.4 Prevalence rates up
to 29% have been reported for PAD in the United States,
depending on the age of the study cohort, the underlying
atherosclerosis risk factor profile, and the presence of
cardiovascular comorbidities.5 In patients with PAD,
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936statin use has been demonstrated to favorably influence
leg functioning, walking performance, ankle-brachial
index (ABI) values, symptoms of claudication, and mor-
tality.6-8 The guidelines of the American College of Cardi-
ology(ACC)/American Heart Association (AHA) on the
management of patients with PAD recommend statin treat-
ment in all patients with PAD to achieve a target low-density
lipoprotein (LDL) cholesterol level 100 mg/dL.4
Despite the use of statin therapy, mortality and mor-
bidity among patients with PAD remain high.5 In addition,
patients with low ABI values are at risk of progressive renal
dysfunction that may be due to the underlying atheroscle-
rotic risk profile.9 Statins may also exert a renoprotective
effect in these patients.
We hypothesized that intensive statin treatment improves
outcome in patientswith PADandmay have a beneficial effect
on long-term outcome owing to properties other than reduc-
ing cholesterol levels. We therefore initiated a large observa-
tional cohort study in patients with PAD to determine the
independent effect of high-dose statin therapy and low target
LDL cholesterol levels on all-cause mortality, cardiac death,
and progression to kidney dysfunction during a long-term
follow-up period. We used propensity analysis to adjust for
selection bias in the comparison of treatments.
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Study design and participants. This was a single-
center observational cohort study of 1374 consecutive pa-
tients with PAD who were referred to our university clinic
for ABI measurement, clinical evaluation, and therapeutic
management between January 1990 and January 2005.
Patients presented with typical symptoms of PAD, includ-
ing typical intermittent claudication or other symptoms of
chronic arterial insufficiency such as foot ulceration, hair
loss, or reduced capillary refill. Patients eligible for the
study had to be 18 years old, and only patients with an
index ABI of0.90 were included. Patients were excluded
from the study if their history included a myocardial infarc-
tion or coronary revascularization procedure within the
previous 6 months, or if they presented with chronic liver
disease (cirrhosis or hepatitis).
All patients who agreed to participate in the study gave
informed consent. The study was conducted according to
the declaration of Helsinki, and the Institutional Review
Board approved the protocol.
During the first visit, patients were screened for clinical
risk factors, ABI values, 12-lead electrocardiographic ab-
normalities, serum cholesterol levels, and medication use.
Diabetes mellitus was recorded if patients presented with a
fasting glucose level of 7.0 mmol/L or in those who
required treatment. Hypertension was recorded if patients
presented with a blood pressure 140/90 mm Hg or if
they were medically treated for hypertension. Renal dys-
function was recorded if patients presented with a serum
creatinine level 2.0 mg/dL (177 mol/L) or in those
who required dialysis. Smoking included only current
smoking. Clinical data were prospectively collected and
stored in a computerized registry. Risk factor reduction,
lifestyle modification, and a lipid-lowering diet were en-
couraged in all patients presenting with clinical risk factors.
Ankle-brachial index measurement. Systolic blood
pressures in the right and left brachial artery, right and left
dorsalis pedis artery, and right and left posterior tibial artery
were measured by trained technicians using a Doppler
ultrasound instrument with an 8-MHz vascular probe
(Imexdop CT Vascular Doppler, Miami Medical, Glen
Allen, Va). The ABI in the right and left leg was calculated
by dividing the right and the left ankle pressure by the
brachial pressure. The higher of the two brachial blood
pressures was used if a discrepancy in systolic blood pressure
was present. Again, the higher of the dorsalis pedis and
posterior tibial artery pressure was used when a discrepancy
in systolic blood pressure between the two arteries was
measured. If no pressure in the dorsalis pedis artery was
obtained owing to a congenitally absent or occluded dor-
salis pedis artery, the pressure in the posterior tibial artery
was used.
The ABI was measured after the participants had been
resting in the supine position for at least 10 minutes. The
lower of the ABI values obtained in each leg was used in all
analyses. Interobserver and intraobserver agreement for the
ABI was 97% and 98%, respectively.Statin therapy and cholesterol measurements.
During the initial visit, patients were screened for statin use.
The duration of statin treatment before enrollment was
recorded in patients who were already being treated with
statins (long-term statin users). In nonstatin users present-
ing with indications for cholesterol reduction, statins were
prescribed according to standard guidelines of the Erasmus
Medical Center for first-time statin users. According to
these guidelines, statin treatment was indicated in patients
with hypercholesterolemia (LDL cholesterol 200 mg/
dL). After 2003, LDL cholesterol level was targeted to
levels 100 mg/dL.
During the initial visit, the daily dosage of statin ther-
apy was recorded and converted to a percentage value of the
maximum recommended therapeutic dose according to the
United States Food and Drug Administration Center for
Drug Evaluation and Research database.10 During follow-
up, patients were monitored for medication adherence and
for the occurrence of side effects, which included myop-
athy, elevated serum transaminases, rhabdomyolysis, pro-
teinuria, and diarrhea or nausea. Serial cholesterol levels
were measured at 6 months and yearly after the initial visit.
Measurements were obtained with an automated enzy-
matic method and included levels of LDL and high-density
lipoprotein (HDL) cholesterol, triglycerides, and total cho-
lesterol. Cholesterol measurements at 6 months were ob-
tained in all patients, and these values were used for survival
analysis. Cholesterol measurements were obtained in 1281
patients (93%) at 1 year, in 1219 patients (89%) at 2 years,
and in 1110 patients (81%) at 3 years.
Definition of study end points. Primary end points
were all-cause mortality and cardiac death. Information
about the patient’s vital status was obtained at the Office of
Civil Registry. For patients who died at our hospital during
follow-up, hospital records and autopsy results were re-
viewed. For patients who died outside our hospital, death
certificates were reviewed and general practitioners were
approached to ascertain the cause of death. A cardiac cause
of death was defined as death caused by cardiac arrhyth-
mias, congestive heart failure, or acute myocardial infarc-
tion. Acute myocardial infarction was defined by postmor-
tem evidence or the presence of at least two of the following
factors 4 weeks before death:
1. elevated cardiac enzyme levels, defined as creatine kinase
(CK) level 190 U/L and CK-MB 14 U/L, or
CK-MB fraction10% of total CK, or cardiac troponin
T 0.1 ng/mL;
2. development of typical electrocardiographic changes,
defined as new Q waves 1 mm or  30 milliseconds;
and
3. typical symptoms of angina pectoris.
Sudden unexpected death in a previously stable patient was
also considered cardiac death if pathology did not reveal a
conclusive cause of death.
The secondary end point was progression to kidney
failure. Serum creatinine measurements were regularly ob-
tained during follow-up visits and the estimated glomerular
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equation: glomerular filtration rate (mL/[min · 1.73 m2]
186  (serum creatinine level) – 1.154  (age) –0.203 
(0.742 if female)  (1.210 if of African descent).11 Kidney
failure was defined as eGFR 15 ml/(min · 1.73 m2) or a
need to start kidney replacement therapy, which included
dialysis or renal transplantation.
Data analysis. Continuous data were compared using
the Student t test or the Mann-Whitney U test, when
appropriate. Categoric data were compared using the 2
test. Group comparisons were performed with analysis of
variance techniques. Univariate and multivariate Cox pro-
portional hazard regression analysis was used to evaluate
the effect of statin therapy and cholesterol levels on the
study end points. All clinical risk factors were entered in
multivariate analysis, irrespective of the significance level in
univariate analysis.
Statin therapy was not randomly assigned in these
patients, and the impact of selection bias may distort the
results of our study. Propensity analyses are reliable tools to
correct for selection bias, and the rationale for using pro-
pensity scores has been described previously.12 Therefore,
propensity scores for statin therapy were calculated, which
were constructed by using multiple logistic regression anal-
ysis.
Variables as listed in Table I that were independently
associated with the decision to prescribe statins (P  .25)
were included in the multivariate propensity score. In pro-
pensity analysis, important variables (P  .001) associated
with the prescription of statin therapy were high baseline
LDL cholesterol levels, coronary artery disease, smoking,
male gender, diabetes mellitus, and previous coronary in-
tervention. The propensity score ranged from 0.03 to 0.93.
The Kaplan-Meier method with the log-rank test was used
to assess differences in survival between different groups of
patients. For all tests, a two-sided P  .05 was considered
significant. All analyses were performed using SPSS 11.0
statistical software (SPSS Inc, Chicago, Ill).
RESULTS
Baseline characteristics. Baseline characteristics of
the 1374 study participants are presented in Table I. The
mean age was 61 10 years, and 1001 patients (73%) were
men. The mean ABI was 0.60  0.18 (range, 0.05 to
0.90). An ABI of 0.70 was identified in 1070 patients
(78%). During the initial visit, 285 patients (21%) pre-
sented with long-term statin therapy, and statin therapy was
started in 196 patients (14%). The following statins were
used in our study cohort: simvastatin in 293 patients,
pravastatin in 55, fluvastatin in 15, atorvastatin in 88, and
rosuvastatin in 30. In patients with long-term statin ther-
apy, median duration of statin therapy before enrollment
was 3.1 years (interquartile range, 1.3 to 5.0 years). The
mean ( SD) percentage of maximum recommended dose
was 37% 27% in first-time statin users and 34% 27% in
long-term statin users (P  .30).
Fig 1 demonstrates mean LDL cholesterol levels at
baseline and during follow-up stratified according to no,long-term, or first-time statin use. A reduction of LDL cho-
lesterol at 6 months from baseline values was observed in
900 patients (66%), and 257 (19%) had a LDL-cholesterol
Fig 1. Mean low-density lipoprotein (LDL) cholesterol level at
different times of measurement. Data are presented with standard
error of the mean.
Table I. Baseline characteristics of the patients
Characteristic* Study cohort (n  1374)
Age (years) 61  10
Male gender 1001 (72.9)
Angina pectoris 345 (25.1)
History of
Myocardial infarction 484 (35.2)
Congestive heart failure 102 (7.4)
Coronary artery bypass grafting 264 (19.2)
Percutaneous coronary intervention 84 (6.1)
Stroke or transient ischemic attack 105 (7.6)
Diabetes mellitus 232 (16.9)
Hypertension 602 (43.8)
Current smoking 385 (28.0)
Renal failure 83 (6.0)
COPD 139 (10.1)
Q waves 348 (25.3)
ST segment changes 250 (18.2)
Left bundle branch block 62 (4.5)
Right bundle branch block 30 (2.2)
Ankle-brachial index at rest 0.60  18
Aspirin 353 (25.7)
ACE 397 (28.9)
	-Blocker 443 (32.2)
Calcium-channel blocker 453 (32.9)
Statins 481 (35.0)
Triglyceride level (mg/dL) 194  158
Cholesterol level (mg/dL)
LDL 144  51
HDL 44  19
Total 215  55
LDL/HDL ratio 3.2  1.5
Total cholesterol/HDL ratio 5.3  2.6
COPD, Chronic obstructive pulmonary disease; LDL, low-density lipopro-
tein; HDL, high-density lipoprotein; ACE, angiotensin-converting enzyme
inhibitor.
*Categoric data presented as n (%), continuous data as mean  standard
deviation.reduction of 35%. Higher statin doses were significantly
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coefficient, –0.24, P  .0001). Six months after enroll-
ment, the LDL cholesterol level was 100 mg/dL in 423
patients (30.8%) and 70 mg/dL in 133 patients (9.7%).
Follow-up. During a mean follow-up of 6.4  3.6
years, 404 patients (29%) died, and cardiac death occurred
in 278 (20%). Noncardiac causes of death were renal disease
in 23 patients (2%), respiratory failure in 32 (2%), cancer in
23 (2%), stroke in 21 (2%), sepsis in 12 (1%) and other or
unknown causes in 15 (1%). During follow-up, 68 patients
(5%) progressed to kidney failure.
Statin therapy during follow-up was discontinued in six
patients (1%) owing to myopathy and in 3 patients (1%)
because of nausea or diarrhea, or both.
Kaplan-Meier survival curves demonstrate that first-
time and long-term statin users were at significantly lower
risk for all-cause mortality (P  .001) and cardiac death
(P  .001) compared with patients who were not using
statins (Fig 2). An improved survival (P  .001) and
freedom from cardiac death (P .001) was also observed in
patients who were taking higher doses of statin (Fig 3). Fig 4
Fig 2. Kaplan-Meier curves for (A) all-cause mortality (B) and
cardiac death, stratified according to the duration of statin therapy.demonstrates that all-cause mortality (15%) and cardiacdeath (10%) were lowest in patients with the largest per-
centage LDL cholesterol reduction (reduction 35%; P 
.001 and P  .001, respectively).
Fig 5 demonstrates the incidence of overall and cardiac
mortality stratified according to different LDL cholesterol
levels at 6 months. The lowest all-cause mortality rate
(18%) and cardiac death rate (13%) was observed in the
patients with LDL cholesterol levels 70 mg/dL (P 
.001 and P  .001, respectively). Overall and cardiac
mortality rates were gradually increasing in patients with
higher 6-month LDL cholesterol levels (P .001 and P
.001, respectively).
Multivariate analysis. Cox hazard regression analysis
with adjustment for clinical variables, ABI values, electro-
cardiography, and propensity scores demonstrated that
long-term statin therapy, higher doses of statin therapy,
Fig 3. Kaplan-Meier curves for (A) all-cause mortality (B) and
cardiac death stratified according to the dose of statin therapy,
expressed as percentage of maximum recommended therapeutic
dose.larger reductions in LDL cholesterol during the first 6
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significantly associated with a lower risk of overall and
cardiac mortality (Tables II and III). Higher triglyceride
concentrations, higher total cholesterol levels, a higher
LDL/HDL cholesterol ratio, and a higher total/HDL
cholesterol ratio at 6 months also proved to be significantly
correlated with a higher all-cause and cardiac mortality rate
(Tables II and III). Higher mean cholesterol levels during
follow-up were also significantly associated with adverse
outcome (Tables II and III).
A final multivariate model including statin dose, base-
line, and 6-month cholesterol levels supported our hypoth-
esis that higher statin doses (per 10% increase) and lower
6-month LDL cholesterol levels (per 10 mg/dL decrease)
were both independently associated with lower all-cause
mortality (hazard ratio [HR], 0.71; 95% confidence inter-
val [CI], 0.62 to 0.80; andHR, 0.96; 95%CI, 0.93 to 0.98,
respectively) and cardiac death (HR, 0.76; 95% CI, 0.67 to
0.86; and HR 0.95; 95% CI, 0.92 to 0.98, respectively).
Secondary end point outcome. Multivariate analysis
demonstrated that first time statin users and long-time
statin users were at a lower risk of progression to kidney
failure compared with patients not using statins (HR, 0.16;
95% CI, 0.04 to 0.65; andHR, 0.29; 95% CI, 0.12 to 0.71,
respectively). Higher doses of statin therapy were associ-
ated with a lower occurrence of the secondary end point of
kidney failure (HR per 10% increase: 0.69; 95% CI, 0.54 to
0.89), independent of baseline characteristics and choles-
terol levels. In the same model, a nonsignificant association
was observed between lower 6-month LDL cholesterol
levels (per 10 mg/dL decrease) and a lower rate of kidney
failure (HR, 0.97; 95% CI, 0.91 to 1.03).
DISCUSSION
The present study shows that intensified statin therapy
and lower target LDL-cholesterol levels are significantly
associated with improved survival in patients with PAD.
The beneficial effects of higher statin doses and lower target
LDL cholesterol levels were independent of each other and
independent of the presence of clinical risk factors, ABI
Fig 4. The estimated incidence of overall mortality and cardiac
death at 10 years of follow-up in patients with no, low (1% to 35%)
and high (35%) 6-month low-density lipoprotein (LDL) choles-
terol reduction from baseline values.values, electrocardiography, and propensity scores for statintherapy. These findings suggest the importance of achiev-
ing low target LDL cholesterol levels in patients with PAD.
They also suggest that statins have beneficial long-term
effects owing to properties other than reducing cholesterol
levels.
Statins in peripheral arterial disease. TheHeart Pro-
tection Study provided convincing evidence that 40 mg of
daily simvastatin significantly lowered the risk of vascular
events in 6748 patients with PAD compared with placebo.13
During 5 years of follow-up, first major vascular events
were observed in 26% of statin users vs 33% in placebo-
allocated patients.13 Schillinger et al14 also demonstrated
that statin therapy was associated with improved survival in
patients with severe PAD with elevated high-sensitivity
C-reactive protein levels. Several earlier studies have con-
firmed the beneficial effects of statins on symptoms of
claudication, walking performance, ABI values, and leg
functioning.6-8
Low-density lipoprotein cholesterol threshold in
coronary artery disease. The National Cholesterol Edu-
cation Program (NCEP) Adult Treatment Panel III guide-
lines and the European guidelines on cardiovascular disease
prevention in clinical practice recommend a target LDL
cholesterol level of 100 mg/dL in people with (risk
equivalents of) coronary artery disease.15,16 Recent clinical
trials have shown the beneficial effect of LDL cholesterol
levels 100 mg/dL on cardiovascular outcome. The
Treating to New Targets trial showed that intensive lipid-
lowering therapy with 80 mg of daily atorvastatin signifi-
cantly reduced first major cardiovascular event rate during a
median follow-up of 5 years compared with 10 mg of daily
atorvastatin (8.7% vs 10.9%, respectively).17 Mean LDL
cholesterol levels were 77 mg/dL during 80-mg atorvasta-
tin treatment and 101 mg/dL during 10-mg atorvastatin
treatment.17
Cannon et al18 enrolled patients after acute coronary
syndromes and compared 40 mg of pravastatin with 80 mg
of atorvastatin.18 Median LDL cholesterol levels during
Fig 5. The estimated incidence of overall mortality and cardiac
death at 10 years of follow-up in patients with varying low-density
lipoprotein (LDL) cholesterol levels after 6 months of study
enrollment.treatment were 95 mg/dL and 62 mg/dL, respectively.
easu
measu
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ratio was found in favor of atorvastatin. Nissen et al19
demonstrated that intensive treatment with 80 mg of ator-
Table II. Univariate and multivariate Cox proportional ha
Variable HR (95% C
Statin therapy at enrollment
No statins (reference group) 1.0
First-time statin therapy 0.42 (0.30-0
Long-term statin therapy 0.27 (0.18-0
Statin dose (per 10% increase)† 0.70 (0.63-0
LDL reduction (per 10%)‡ 0.94 (0.91-0
Cholesterol levels (6 months)
LDL (per 10 mg/dL decrease) 0.96 (0.93-0
HDL (per 10 mg/dL increase) 0.94 (0.87-1
Triglycerides (per 10 mg/dL decrease) 0.99 (0.98-1
Total (per 10 mg/dL decrease) 0.94 (0.92-0
LDL/HDL 1.16 (1.08-1
Total/HDL 1.12 (1.06-1
Mean cholesterol levels (follow-up)
LDL (per 10 mg/dL decrease) 0.94 (0.92-0
HDL (per 10 mg/dL increase) 0.89 (0.82-0
Triglycerides (per 10 mg/dL decrease) 0.99 (0.98-1
Total (per 10 mg/dL decrease) 0.94 (0.91-0
LDL/HDL 1.26 (1.17-1
Total/HDL 1.16 (1.08-1
HR, Hazard ratio; CI, confidence interval; LDL, low-density lipoprotein; H
*Adjusted for clinical risk factors, ankle-brachial index values, electrocardio
†Expressed as percentage of maximum recommended therapeutic dose.
‡The relative reduction (%) in LDL cholesterol at 6-months from baseline m
Table III. Univariate and multivariate Cox proportional h
Variable HR (95% C
Statin therapy at enrollment
No statins (reference group) 1.0
First-time statin therapy 0.53 (0.36-0
Long-term statin therapy 0.34 (0.22-0
Statin dose (per 10% increase)† 0.74 (0.67-0
LDL reduction (per 10%)‡ 0.95 (0.91-0
Cholesterol levels (6 months)
LDL (per 10 mg/dL decrease) 0.95 (0.92-0
HDL (per 10 mg/dL increase) 0.91 (0.88-0
Triglycerides (per 10 mg/dL decrease) 0.98 (0.98-0
Total (per 10 mg/dL decrease) 0.93 (0.90-0
LDL/HDL 1.16 (1.07-1
Total/HDL 1.15 (1.09-1
Mean cholesterol levels (follow-up)
LDL (per 10 mg/dL decrease) 0.93 (0.90-0
HDL (per 10 mg/dL increase) 0.88 (0.80-0
Triglycerides (per 10 mg/dL decrease) 0.99 (0.98-1
Total (per 10 mg/dL decrease) 0.92 (0.89-0
LDL/HDL 1.23 (1.13-1
Total/HDL 1.19 (1.10-1
HR, Hazard ratio; CI, confidence interval; LDL, low-density lipoprotein; H
*Adjusted for clinical risk factors, ankle-brachial index values, electrocardio
†Expressed as percentage of maximum recommended therapeutic dose.
‡The relative reduction (%) in LDL-cholesterol at 6-months from baselinevastatin (mean LDL cholesterol level, 79 mg/dL) reducedthe percentage change in atheroma volume compared with
40 mg of pravastatin (mean LDL cholesterol level, 110
mg/dL). Moreover, it has been demonstrated that inten-
s models to predict overall mortality
riate Multivariate*
P HR (95% CI) P
1.0
.001 0.37 (0.25-0.54) .001
.001 0.24 (0.16-0.37) .001
.001 0.69 (0.61-0.77) .001
.001 0.93 (0.90-0.96) .001
.001 0.97 (0.94-0.99) .009
.09 0.94 (0.86-1.03) .17
.02 0.99 (0.98-1.00) .01
.001 0.94 (0.90-0.97) .001
.001 1.13 (1.05-1.22) .001
.001 1.13 (1.07-1.19) .001
.001 0.95 (0.92-0.97) .001
.004 0.90 (0.82-0.98) .02
.1 0.99 (0.98-1.00) .04
.001 0.95 (0.91-0.98) .001
.001 1.24 (1.15-1.34) .001
.001 1.17 (1.07-1.27) .001
igh-density lipoprotein.
and propensity scores.
rements.
ds models to predict cardiac mortality
riate Multivariate*
P HR (95% CI) P
1.0
.001 0.44 (0.29-0.68) .001
.001 0.28 (0.17-0.46) .001
.001 0.71 (0.63-0.80) .001
.01 0.94 (0.90-0.98) .004
.001 0.95 (0.93-0.98) .001
.04 0.90 (0.82-0.98) .01
.001 0.99 (0.98-0.99) .001
.001 0.92 (0.89-0.96) .001
.001 1.15 (1.06-1.25) .001
.001 1.16 (1.10-1.23) .001
.001 0.94 (0.91-0.96) .001
.008 0.87 (0.78-0.96) .008
.01 0.98 (0.97-0.99) .004
.001 0.93 (0.89-0.97) .001
.001 1.22 (1.12-1.34) .001
.001 1.21 (1.10-1.33) .001
igh-density lipoprotein.
and propensity scores.
rements.zard
Univa
I)
.59)
.39)
.77)
.97)
.98)
.01)
.00)
.97)
.24)
.17)
.96)
.97)
.00)
.97)
.35)
.25)
DL, h
graphyazar
Univa
I)
.78)
.52)
.82)
.99)
.98)
.99)
.99)
.96)
.26)
.20)
.96)
.97)
.00)
.96)
.35)
.29)
DL, h
graphysive 40-mg rosuvastatin therapy, with a mean LDL choles-
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cant regression of atherosclerosis during serial intravascular
ultrasound examinations.20
Recommendations in peripheral arterial disease.
After the revision of the NCEP Adult Treatment Panel III
guidelines in July 2004,21 the ACC/AHA has recom-
mended a LDL cholesterol level70 mg/dL in very-high-
risk patients with PAD.4 Very-high-risk patients included
those with established PAD plus multiple major risk factors,
severe and poorly controlled risk factors, or multiple risk
factors of the metabolic syndrome. These recommenda-
tions have mainly been extrapolated from studies including
patients with coronary artery disease or from post hoc
analysis of patients with PAD.13
The current study suggests that all patients with ABIs
of 0.90 may benefit from LDL cholesterol levels 70
mg/dL. Although much attention has given to LDL cho-
lesterol as measure of risk, our study demonstrated that
higher HDL cholesterol, lower triglyceride, lower total
cholesterol, and lower LDL/HDL cholesterol and total/
HDL cholesterol ratio were also significant correlates of
improved survival.
Pleiotropic effects of statins. Higher statin doses
were associated with improved outcome independent of
LDL cholesterol levels in the current study, suggesting that
other than lipid-lowering properties of statins are beneficial
in PAD patients. The cholesterol-independent effects of
statins have been suggested in previous studies. In human
carotid plaques, statins decrease lipids, lipid oxidation, in-
flammation, matrix metalloproteinase 2, and cell death, and
increase tissue inhibitor of metalloproteinase 1 and colla-
gen, suggesting a plaque-stabilizing effect.22 Studies also
demonstrated that statins lower the concentration of C-
reactive protein and improve the outcome in patients with
coronary artery disease, independent of the effect on LDL
cholesterol levels.2,3,23 Long-term intensive statin therapy
should therefore be considered in all patients with PAD.
Statins and renal outcome. Atherosclerosis is now
becoming a recognized cause of renal deterioration. Exper-
imental studies have suggested a preventive effect of statins
on nephropathy by halting extracellular matrix accumula-
tion, overexpression of connective growth factors,24 and
tubular-interstitial fibrosis.25 A meta-analysis showed that
statins can reduce proteinuria or albuminuria, especially in
patients with cardiovascular disease.26
Finally, a recent study demonstrated in 103 consecutive
patients with hyperlipidemia and PAD that creatinine levels
decreased after 3 to 4 months of treatment with simvasta-
tin, independent of the degree of LDL cholesterol reduc-
tion.27 In the current study, every 10% increase in statin
dose was associated with a 31% lower risk of progression to
kidney failure, irrespective of cholesterol levels; however,
these results should be interpreted in the context of the
study design, in which the occurrence of kidney failure was
relatively low (5%).
Study limitations. The findings apply to patients with
PAD referred to a university hospital. Adverse outcome
rates may therefore be higher than in the general popula-tion. The study population consisted mostly of white men
with a high prevalence of cardiovascular risk factors. The
study was observational in nature, and the major limitation
that should be addressed is that statins were not assigned in
a random fashion. We did, however, use multivariate anal-
ysis to adjust for known possible confounding factors and
for the propensity to prescribe statin therapy to reduce a
possible selection bias.28
This study did not systematically record the number of
patients who became eligible for statin therapy during
follow-up. Because analysis was based on treatment at
enrollment, the results for statin therapy may have been
underestimated, assuming that all patients with statin treat-
ment continued their medication.
Before recommending low LDL-cholesterol levels and
high statin doses in all patients with PAD, it should be
noted that concerns about the safety of very low cholesterol
levels have been raised because cholesterol plays an impor-
tant role in cell membrane composition and in neuronal
and optic development. In addition, higher statin doses
may result in higher rates of side effects, such as treatment-
related myalgia and liver toxicity.29 Future studies should
further evaluate the safety of high-dose statin therapy and
very-low LDL-cholesterol concentrations in patients with
PAD.
CONCLUSION
The current prospective observational cohort study of
1374 patients with peripheral arterial disease demonstrated
that intensified statin therapy and lower target LDL cho-
lesterol levels are independently associated with improved
outcome. Target LDL cholesterol levels70 mg/dL were
associated with the lowest rate of overall mortality and
cardiac mortality during a mean follow-up of 6 years.
Higher statin doses were also associated with a lower oc-
currence of progression to kidney failure. The current
results support the view that statins have beneficial effects
beyond their lipid lowering properties and should be con-
sidered in all patients with PAD, irrespective of LDL cho-
lesterol levels.
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